INGN 201

Identification

Name
INGN 201
Accession Number
DB05322
Type
Biotech
Groups
Investigational
Biologic Classification
Protein Based Therapies
Other protein based therapies
Description

INGN 201(Advexin) is a replication-impaired adenoviral vector that carries the p53 gene, has been evaluated in both preclinical and clinical trials. Advexin is a well-tolerated and efficacious treatment for numerous cancers, both as monotherapy and in combination with radiation and/or chemotherapy agents.

Protein chemical formula
Not Available
Protein average weight
Not Available
Sequences
Not Available
Synonyms
Not Available
International/Other Brands
Advexin
Categories
UNII
Not Available
CAS number
Not Available

Pharmacology

Indication

Investigated for use/treatment in bladder cancer, brain cancer, breast cancer, esophageal cancer, head and neck cancer, lung cancer, oral cavity cancer, ovarian cancer, and prostate cancer.

Pharmacodynamics
Not Available
Mechanism of action

Advexin® is a vaccine that contains very high concentrations of the p53 protein. Advexin® is administered into or near the site of cancer and has demonstrated the ability to make cancer cells more sensitive to the killing effects of chemotherapy. The p53 gene makes protein that is responsible for stopping uncontrolled growth of a cell. One of its roles is to stop growth of a cell and initiate repair of any detected mutations or damage within the DNA of the cell. In addition, the p53 gene will direct the cell to destroy itself if a mutation or damage is detected that is beyond repair.

Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when 16-Bromoepiandrosterone is combined with INGN 201.
19-norandrostenedioneThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with INGN 201.
2-MethoxyethanolThe risk or severity of adverse effects can be increased when 2-Methoxyethanol is combined with INGN 201.
5-androstenedioneThe risk or severity of adverse effects can be increased when 5-androstenedione is combined with INGN 201.
AbataceptThe risk or severity of adverse effects can be increased when Abatacept is combined with INGN 201.
AbetimusThe risk or severity of adverse effects can be increased when Abetimus is combined with INGN 201.
AbituzumabThe therapeutic efficacy of INGN 201 can be decreased when used in combination with Abituzumab.
ActeosideThe risk or severity of adverse effects can be increased when Acteoside is combined with INGN 201.
AdecatumumabThe therapeutic efficacy of INGN 201 can be decreased when used in combination with Adecatumumab.
AdefovirThe risk or severity of adverse effects can be increased when Adefovir is combined with INGN 201.
Food Interactions
Not Available

References

General References
  1. Authors unspecified: INGN 201: Ad-p53, Ad5CMV-p53, adenoviral p53, p53 gene therapy--introgen, RPR/INGN 201. Drugs R D. 2007;8(3):176-87. [PubMed:17472413]
  2. Gabrilovich DI: INGN 201 (Advexin): adenoviral p53 gene therapy for cancer. Expert Opin Biol Ther. 2006 Aug;6(8):823-32. [PubMed:16856803]
External Links
PubChem Substance
347910081

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentMetastatic Bladder Cancer / Recurrent Bladder Cancer / Stage I Bladder Cancer / Stage II Bladder Cancer / Stage III Bladder Cancer / Transitional Cell Carcinoma of the Bladder1
1, 2CompletedPreventionLip and Oral Cavity Cancer / Oropharyngeal Cancers / Stage 0 Lip and Oral Cavity Cancer / Stage 0 Oropharyngeal Cancer / Tongue Cancer1
2TerminatedTreatmentHead and Neck Carcinoma1
Not AvailableWithdrawnDiagnosticCancer, Breast1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available

Taxonomy

Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available

Drug created on November 18, 2007 11:23 / Updated on October 01, 2018 14:00